Those who will live 1,000 years have already been born! They will not only live long, but will be healthy and active throughout life! This will already be possible in the transition phase of building the Creative Society!
We will talk about it in a live conversation with British biogerontologist Aubrey de Grey. In this new episode of Health Navigator, you will find out the answers to these questions:
But what would it actually mean to transfer your mind from “meat space” to cyberspace, and how could it be done? The basic idea rests on several assumptions, says Angela Thornton, a researcher at the Horizon Centre for Doctoral Training at University of Nottingham, who is also partnered with the Carboncopies Foundation, a non-profit that focuses on “whole brain emulation” and the creation of substrate-independent minds. “It assumes that we could replicate our brain [with] a certain level of understanding of how it works,” she says. “Not necessarily knowing all the detail, but enough to be able to emulate it.” Then, she adds, we have to make the assumption that the “mind” (i.e. the abstract part of us that thinks, remembers, imagines and senses) naturally emerges from the structures of the physical brain.
This is a lot to take on, which is partly why current brain emulation research is still stuck at the level of worms and, in more advanced studies, mice. Whether you agree with them or not, though, the arguments to take experiments further – toward larger mammals and, finally, humans – are quite obvious. For one, we could theoretically ‘live’ forever as a disembodied consciousness (or at least until the machines that hosted our virtual minds were destroyed), and continue interacting with our loved ones after they’ve passed as well. It’s possible that this could also go some way to solving the alleged population crisis, while limiting the impact of our physical bodies on the planet’s finite resources.
A “chaperone” molecule that slows the formation of certain proteins reversed disease signs, including memory impairment, in a mouse model of Alzheimer’s disease, according to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.
In the study, published in Aging Biology, researchers examined the effects of a compound called 4-phenylbutyrate (PBA), a fatty-acid molecule known to work as a “chemical chaperone” that inhibits protein accumulation. In mice that model Alzheimer’s disease, injections of PBA helped to restore signs of normal proteostasis (the protein regulation process) in the animals’ brains while also dramatically improving their performance on a standard memory test, even when administered late in the disease course.
“By generally improving neuronal and cellular health, we can mitigate or delay disease progression,” said study senior author Nirinjini Naidoo, Ph.D., a research associate professor of Sleep Medicine. “In addition, reducing proteotoxicity— irreparable damage to the cell that is caused by an accumulation of impaired and misfolded proteins—can help improve some previously lost brain functions.”